In clinical practice, the molecular subtyping of breast cancer (BC) relies on immunohistochemistry (IHC) to measure the protein expression of estrogen receptor ER/ESR1, progesterone receptor PR/PGR, human epidermal growth factor receptor 2 HER2/ERBB2, and marker of proliferation Ki67/MKI67 [1]. Here, MKI67 is linked to breast carcinoma.